The FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 3 to 6 against recommending camizestrant in combination with a CDK4/6 inhibitor
Stroke is the second-leading cause of death and the third-leading cause of disability worldwide
The company posted revenue of €1,267 million, up 6% on a constant currency basis
Under the terms, Arcellx shareholders received $115 per share in cash plus a non-transferable contingent value right
The 4,000-square-foot facility is designed as a hands-on hub where customers can work directly with scientists and engineers
The microbiology unit generated $645 million in revenue in 2025 and sits within Thermo Fisher’s Specialty Diagnostics segment
But acquisition charges drag earnings into loss
The transaction marks a clear portfolio reshuffle for Indoco
While Drugs for Neglected Diseases initiative (DNDi) drives the R&D for neglected diseases, we collaborate with pharmaceutical companies at multiple stages, including sourcing promising molecules
Wadhwa brings over two decades of experience driving growth, transformation, and customer-centric strategies in the medical devices and diagnostics sector
Subscribe To Our Newsletter & Stay Updated
